Promore Pharma´s CFO leaves the company in 2020
STOCKHOLM, 2 April 2020 -- Promore Pharma’s CFO Jenni Björnulfson has announced that she has decided to leave her role in the company for a position in another company.
“The Board of Directors and I would like to thank Jenni for her commitment and efforts during the years she has worked for Promore Pharma. It's sad that Jenni leaves, but I wish her good luck in her new endeavors," says Jonas Ekblom, President and CEO of Promore Pharma. “We are well equipped to immediately start a recruitment process to secure a replacement for Jenni”, he continues.
Jenni Björnulfson will remain in her current role during her six months long notice period.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
Email: jonas.ekblom@promorepharma.com
Jenni Björnulfson, CFO
Phone: [+46] 708 55 38 05
Email: jenni.bjornulfson@promorepharma.com
Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se
The information was submitted for publication, through the agency of the contact persons set out above, on 2 April 2020 at 11.00 CET.
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 is performing a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.